Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study

This publication has 29 references indexed in Scilit:

• Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis
  European Urology Oncology, 2023
• Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
  European Urology Open Science, 2023
• Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis
  Medical Oncology, 2022
• Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors
  European Journal of Cancer, 2022
• PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence
  Cancer Treatment Reviews, 2022
• Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib
  European Urology, 2021
• DNA Repair and Prostate Cancer: A Field Ripe for Harvest
  European Urology, 2020
• Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
  Cell, 2018
• Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
  The Journal of Molecular Diagnostics, 2017
• Integrative Clinical Genomics of Advanced Prostate Cancer
  Cell, 2015